Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026

SUTRO BIOPHARMA, INC.

2026-Q1 EPS reported -$2.94 revenue$14,523,000

Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.
Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).
STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.
Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.
Luvelta program closed; no further investment or business development efforts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

SUTRO BIOPHARMA, INC. reported financial results for the first quarter of 2026.

Period: the first quarter of 2026
Result: reported results

Exact text from the filing

Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-224065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.